Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
Keywords: Alzheimer's disease; Angiogenesis; Anti-Angiogenic Therapy; Bevacizumab; FITC-albumin; Huntington's disease; MMPs; Microglia; PEA; Pegaptanib; Ranibizumab; S1P; Sphingosine-1-phosphate; TIMPs; TNF; VEGF; aetiopathogenesis; angiogenesis; angiopathy; blood-brain barrier; central nervous system; embryonic neuroectoderm; encephalomyelitis; gliosis; hippocampus; hypoxia; ischemia; lactobionamide; lactobionolactone; maculophathy; metalloproteinases; multiple sclerosis; neurodegeneration; palmitoylethanolamide; prostaglandins; retina; vascular endothelial frowth factor; vasculogenesis; vasodilation
Document Type: Research Article
Publication date: 2010-12-01
- CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.